Rocket Pharmaceuticals (RCKT) Tops Q4 EPS by 5c

Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q4 EPS of ($0.38), $0.05 better than the analyst estimate of ($0.43).

For earnings history and earnings-related data on Rocket Pharmaceuticals (RCKT) click here.

You May Also Be Interested In

• Trump on Iran: we're trying to work out a deal that's fair
• Tellus Power and Nayax partner on integrated EV charging platform
• Coherus and Zumutor to run Phase 1 trial combining ZM008 and Loqtorzi